487 Results

People

  1. De Angelis
    De Angelis
  2. Abrey
    Abrey
  3. Kelsen
    Kelsen
  4. Lichtman
    Lichtman
  5. Bajorin
    Bajorin
  6. Perales
    Perales
  7. Yahalom
    Yahalom
  8. Saltz
    Saltz
  9. Seidman
    Seidman
  10. Correa
    Correa

Groups

  1. Department of Medicine (257)
  2. Solid Tumor Oncology Division (171)
  3. Hematologic Malignancies, Division of (102)
  4. Center for Hematologic Malignancies (89)
  5. Survivorship Research (72)
  6. Tow Center for Developmental Oncology (TCDO) (51)
  7. Gastrointestinal Oncology Service (50)
  8. Surgery (45)
  9. Genitourinary Oncology Service (42)
  10. Bone Marrow Transplant (38)
  1. "neurotoxicity"
Formats
  1. Journal Article (426)
  2. Review (34)
  3. Editorial (6)
  4. Conference Paper (5)
  5. Book Section (4)
  6. Correspondence (4)
  7. Guidelines (3)
  8. Meeting Abstract (2)
  9. Research Letter (2)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (257)
  2. Solid Tumor Oncology Division (171)
  3. Hematologic Malignancies, Division of (102)
  4. Center for Hematologic Malignancies (89)
  5. Survivorship Research (72)
  6. Tow Center for Developmental Oncology (TCDO) (51)

More Groups

People
  1. Lisa De Angelis (44)
  2. Lauren Abrey (29)
  3. David Kelsen (19)
  4. Stuart Lichtman (18)
  5. Dean Bajorin (17)
  6. Joachim Yahalom (17)

More People

Years
  1. 2025 (25)
  2. 2024 (26)
  3. 2023 (18)
  4. 2022 (10)
  5. 2021 (5)
  6. 2020 (6)

More Years

Publications
  1. Journal of Clinical Oncology (46)
  2. Cancer (19)
  3. Seminars in Oncology (15)
  4. Gynecologic Oncology (13)
  5. Journal of Neuro-Oncology (13)
  6. Blood (11)

More Publications

Publishers
  1. Elsevier Inc. (80)
  2. American Society of Clinical Oncology (47)
  3. Springer (41)
  4. Nature Publishing Group (28)
  5. Wiley Blackwell (27)
  6. Lippincott Williams & Wilkins (26)

More Publishers

Results (487)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Incidence, mitigation, and management of neurologic adverse events in the CARTITUDE-2 study of patients with multiple myeloma treated with ciltacabtagene autoleucel (cilta-cel)
    Meeting Abstract

    Jakubowiak, A.; Parekh, S.; Madduri, D.; Santomasso, B.; Perez-Larraya, J. G.; van de Donk, N. W. C. J.; Arnulf, B.; Mateos, M. V.; De Braganca, K. C.; Varsos, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: A multi-center case series
    Journal Article

    Rajendram, P.; Torbic, H.; Duggal, A.; Campbell, J.; Hovden, M.; Dhawan, V.; Pastores, S. M.; Gutierrez, C.
    Journal of Critical Care (2021)

    Fulltext@MSK | Save
  • Predictors for neurotoxicity on day of infusion of chimeric antigen receptor (CAR) T cells using discovery proteomics platform
    Meeting Abstract

    Lakkaraja, M.; Hosszu, K.; McAvoy, D.; Mauguen, A.; Purdon, T. J.; Auchincloss, T.; Klein, E.; Khakoo, Y.; Santomasso, B.; Senechal, B.; more...
    Cytotherapy (2021)

    Fulltext@MSK | Save
  • Toxicities associated with immunotherapy and approach to cardiotoxicity with novel cancer therapies
    Review

    Gutierrez, C.; Rajendram, P.; Pastores, S. M.
    Critical Care Clinics (2021)

    Fulltext@MSK | Save
  • Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma
    Journal Article

    Pasquini, M. C.; Hu, Z. H.; Curran, K.; Laetsch, T.; Locke, F.; Rouce, R.; Pulsipher, M. A.; Phillips, C. L.; Keating, A.; Frigault, M. J.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: A practical overview
    Review

    Mohty, M.; Dulery, R.; Gauthier, J.; Malard, F.; Brissot, E.; Aljurf, M.; Bazarbachi, A.; Chabanon, C.; Kharfan-Dabaja, M. A.; Savani, B. N.; more...
    Bone Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma
    Journal Article

    Wudhikarn, K.; Palomba, M. L.; Pennisi, M.; Garcia-Recio, M.; Flynn, J. R.; Devlin, S. M.; Afuye, A.; Silverberg, M. L.; Maloy, M. A.; Shah, G. L.; more...
    Blood Cancer Journal (2020)

    Fulltext@MSK | Save
  • Neurological complications of chemotherapy
    Book Section

    Diaz, M.; Schiff, D.
    In Ahluwalia, M.; Metellus, P.; Soffietti, R. (Eds.) Central Nervous System Metastases (2020)

    Fulltext@MSK | Save
  • The advent of CAR T-cell therapy for lymphoproliferative neoplasms: Integrating research into clinical practice
    Review

    Cerrano, M.; Ruella, M.; Perales, M. A.; Vitale, C.; Faraci, D. G.; Giaccone, L.; Coscia, M.; Maloy, M.; Sanchez-Escamilla, M.; Elsabah, H.; more...
    Frontiers in Immunology (2020)

    Fulltext@MSK | Save
  • The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities
    Journal Article

    Gutierrez, C.; Brown, A. R. T.; Herr, M. M.; Kadri, S. S.; Hill, B.; Rajendram, P.; Duggal, A.; Turtle, C. J.; Patel, K.; Lin, Y.; more...
    Journal of Critical Care (2020)

    Fulltext@MSK | Save